FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma By Ogkologos - January 28, 2026 338 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR How Does COVID-19 Affect People with Cancer? NCCAPS Will Help Find... May 21, 2020 Biomarkers of Pro-Inflammatory Response May Identifiy Cancer Patients at Risk of... November 21, 2020 FDA Approves First Immunotherapy Treatment For Breast Cancer March 11, 2019 EMA Recommends Granting a Marketing Authorisation for Tucatinib December 22, 2020 Load more HOT NEWS How can we improve LGBTQ+ cancer care? – That Cancer Conversation Bowel scope screening to stop in England Trastuzumab Deruxtecan Shows High Intracranial Response Rate in Patients with Active... Responding to Coronavirus, Cancer Researchers Reimagine Clinical Trials
